EOElisa Orioli

Elisa Orioli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisa Orioli has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Donato Gemmati

    Department of Translational Medicine, University of Ferrara, Ferrara, Italy, Italy

    8 shared publications
  • Giulia Zeri

    Centre for Haemostasis & Thrombosis, Haematology Section, Department of Medical Sciences, University of Ferrara, 44100 Ferrara, Italy

    5 shared publications
  • Alessandro Castiglione

    Department of Neurosciences, Otorhinolaryngology Unit, University of Padova, Via Giustiniani 2, 35128, Padova, Italy

    2 shared publications
  • Antonio Cuneo

    Centre of Haemostasis & Thrombosis, Haematology Section, Department of Medical Sciences, University-Hospital of S. Anna, Ferrara, Italy

    2 shared publications
  • Marco Vigliano

    Centre for Haemostasis & Thrombosis, Haematology Section, Department of Medical Sciences, University of Ferrara, 44100 Ferrara, Italy

    2 shared publications
  • Maurizio Leone

    Department of Neuroscience, Istituto di Ricerche Farmacologiche “Mario Negri”, 20156 Milano, Italy

    2 shared publications

Latest Publications

  • P2X7 Receptor as a Therapeutic Target

    by Elena De Marchi, Elisa Orioli, Diego Dal Ben, Elena Adinolfi


  • Open Access

    Sudden Sensorineural Hearing Loss and Polymorphisms in Iron Homeostasis Genes: New Insights from a Case-Control Study

    by Alessandro Castiglione, Andrea Ciorba, Claudia Aimoni, Elisa Orioli, Giulia Zeri, Marco Vigliano, Donato Gemmati

    Background. Even if various pathophysiological events have been proposed as explanations, the putative cause of sudden hearing loss remains unclear.Objectives. To investigate and to reveal associations (if any) between the main iron-related gene variants and idiopathic sudden sensorineural hearing loss.Study Design. Case-control study.Materials and Methods. A total of 200 sudden sensorineural hearing loss patients (median age 63.65 years; range 10–92) were compared with 400 healthy control subjects. The following genetic variants were investigated: the polymorphism c.−8CG in the promoter of the ferroportin gene (FPN1;SLC40A1), the two isoforms C1 and C2 (p.P570S) of the transferrin protein (TF), the amino acidic substitutions p.H63D and p.C282Y in the hereditary hemochromatosis protein (HFE), and the polymorphism c.–582AG in the promoter of theHEPCgene, which encodes the protein hepcidin (HAMP).Results. The homozygous genotype c.−8GG of theSLC40A1gene revealed an OR for ISSNHL risk of 4.27 (CI 95%, 2.65–6.89;P=0.001), being overrepresented among cases.Conclusions. Our study indicates that the homozygous genotypeFPN1−8GG was significantly associated with increased risk of developing sudden hearing loss. These findings suggest new research should be conducted in the field of iron homeostasis in the inner ear.


  • Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker?

    by Giulia Zeri, Elisa Orioli, Rosella Mari, Stefano Moratelli, Marco Vigliano, Jlenia Marchesini, Maria Elena Grossi, Alessandro Pecoraro, Antonio Cuneo, Roberto Ferrari, et al.

    After acute myocardial infarction (MI) the damaged heart has to be repaired. Factor XIII (FXIII) is considered a key molecule in promoting heart healing. FXIII deficiency was associated to cardiac rupture and anomalous remodelling in MI. During MI, FXIII contributes firstly to the intracoronary thrombus formation and shortly after to heal the myocardial lesion. To quantify the real contribution of FXIII in this process, and to explore its possible prognostic role, we monitored the FXIII-A subunit levels in 350 acute MI patients during the first six days (d0-d5) plus a control at 30–60 days (d30). A one-year follow-up was performed for all the patients. A transient drop in the FXIII-A mean level was noted in the whole cohort of patients (FXIII-Ad0 99.48 ± 30.5 vs FXIII-Ad5 76.51 ± 27.02; p< 0.0001). Interestingly, those who developed post-MI heart failure showed the highest drop (FXIII-Ad5 52.1 ± 25.2) and they already presented with low levels at recruitment. Similarly, those who died showed the same FXIII-A dynamic (FXIII-Ad5 54.0 ± 22.5). Conversely, patients who remained free of major adverse cardiac events, had lower consuming (FXIII-Ad0 103.6 ± 29.1 vs FXIII-Ad5 84.4 ± 24.5; p< 0.0001). Interestingly, the FXIII-A drop was independent from the amount of injury assessed by TnT and CKMB levels. The survival analysis ascribed an increased probability of early death or heart failure inversely related to FXIII-A quartiles (FXIII-A25th< 59.5 %; hazard ratio 4.25; 2.2–5.1; p< 0.0001). Different FXIII-A dynamics and levels could be utilised as early prognostic indicators during acute MI, revealing the individual potential to heal and suggesting tailored treatments to avoid heart failure or its extreme consequence. Note: This paper was presented in part at the 14th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, Netherlands, June 29 – July 24, 2013.


  • Open Access

    Karyotype-Phenotype Correlation in Partial Trisomies of the Short Arm of Chromosome 6: A Family Case Report and Review of the Literature

    by A. Castiglione, V. Guaran, L. Astolfi, E. Orioli, G. Zeri, D. Gemmati, R. Bovo, A. Montaldi, A. Alghisi, A. Martini

    The first child (proband) of nonconsanguineous Caucasian parents underwent genetic investigation because she was affected with congenital choanal atresia, heart defects and kidney hyposplasia with mild transient renal insufficiency. The direct DNA sequencing after PCR of the CHD7 gene, which is thought to be responsible for approximately 60-70% of the cases of CHARGE syndrome/association, found no mutations. The cytogenetic analysis (standard GTG banding karyotype) revealed the presence of extrachromosomal material on 10q. The chromosome analysis was completed with array CGH (30 kb resolution), MLPA and FISH, which allowed the identification of three 6p regions (6p.25.3p23 × 3): 2 of these regions are normally located on chromosome 6, and the third region is translocated to the long arm of chromosome 10. The same chromosomal rearrangement was subsequently found in the father, who was affected with congenital ptosis and progressive hearing loss, and in the proband's sister, the second child, who presented at birth with choanal atresia and congenital heart defects. The mutated karyotypes, which were directly inherited, are thought to be responsible for a variable phenotype, including craniofacial dysmorphisms, choanal atresia, congenital ptosis, sensorineural hearing loss, heart defects, developmental delay, and renal dysfunction. Nevertheless, to achieve a complete audiological assessment of the father, he underwent further investigation that revealed an increased level of the coagulation factor XIII (300% increased activity), fluctuating levels of fibrin D-dimer degradation products (from 296 to 1,587 ng/ml) and a homoplasmic mitochondrial DNA mutation: T961G in the MTRNR1 (12S rRNA) gene. He was made a candidate for cochlear implantation. Preoperative high-resolution computed tomography and magnetic resonance imaging of the temporal bone revealed the presence of an Arnold-Chiari malformation type I. To the best of our knowledge, this study is the second report on partial 6p trisomy that involves the 10q terminal region. Furthermore, we report the first case of documented Arnold-Chiari malformation type I and increased factor XIII activity associated with 6p trisomy. We present a comprehensive report of the familial cases and an exhaustive literature review.


  • Open Access

    Investigation of in vitro cytotoxicity of the redox state of ionic iron in neuroblastoma cells

    by Ajay Vikram Singh, Varun Vyas, Erica Montani, Daniele Cartelli, Dario Parazzoli, Amanda Oldani, Giulia Zeri, Elisa Orioli, Donato Gemmati, Paolo Zamboni

    Background: there is an intimate relation between transition metals and cell homeostasis due to the physiological necessity of metals in vivo. Particularly, iron (ferrous and ferric state) is utilized in many physiological processes of the cell but in excess has been linked with negative role contributing in many neurodegenerative processes. Objective: the aim of this study was to investigate which oxidation state of ionic iron (Ferrous (II) versus Ferric (III)) is more toxic to neuronal cells (SHSY5Y). Materials and Methods: The neuroblastoma (SHSY5Y) cells were exposed to varying concentration of ferric and ferrous iron. Morphological studies using immunofluorescence staining and microscopic analysis as confirmed by intracellular glutathione (GSH) test demonstrated oxidative stress to cells in iron microenvironment. In addition, MTT assay was performed to evaluate the viability and metabolic state of the cells. Results: the results showed that ferrous form has significantly higher toxicity compared to the ferric ionic state of higher concentration. In addition, microscopic analysis shows cell fenestration at higher concentrations and swelling at intermediate ferric dosages as demonstrated by atomic force microscopy (AFM). Interestingly, the addition of a differentiation inducing factor, trans-retinoic rcid (RA) retains significant viability and morphological features of the cells irrespective of the ionic state of the iron. AFM images revealed clustered aggregates arising from iron chelation with RA. Conclusions: the results indicate that Fe (II) has more toxic effects on cells. In addition, it could be an interesting finding with respect to the antioxidant properties of RA as a chelating agent for the neurodegenerative therapeutics.


  • Open Access

    Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis

    by Donato Gemmati, Giulia Zeri, Elisa Orioli, Francesca E De Gaetano, Fabrizio Salvi, Ilaria Bartolomei, Sandra D’alfonso, Claudia Dall’osso, Maurizio A Leone, Ajay V Singh, et al.

    Iron involvement/imbalance is strongly suspected in multiple sclerosis (MS) etiopathogenesis, but its role is quite debated. Iron deposits encircle the veins in brain MS lesions, increasing local metal concentrations in brain parenchyma as documented by magnetic resonance imaging and histochemical studies. Conversely, systemic iron overload is not always observed. We explored the role of common single nucleotide polymorphisms (SNPs) in the main iron homeostasis genes in MS patients. By the pyrosequencing technique, we investigated 414 MS cases [Relapsing-remitting (RR), n=273; Progressive, n=141, of which: Secondary (SP), n=103 and Primary (PP), n=38], and 414 matched healthy controls. Five SNPs in 4 genes were assessed: hemochromatosis (HFE: C282Y, H63D), ferroportin (FPN1: -8CG), hepcidin (HEPC: -582AG), and transferrin (TF: P570S). The FPN1-8GG genotype was overrepresented in the whole MS population (OR=4.38; 95%CI, 1.89-10.1; P<0.0001) and a similar risk was found among patients with progressive forms. Conversely, the HEPC -582GG genotype was overrepresented only in progressive forms (OR=2.53; 95%CI, 1.34-4.78; P=0.006) so that SP and PP versus RR yielded significant outputs (P=0.009). For almost all SNPs, MS disability score (EDSS), severity score (MSSS), as well as progression index (PI) showed a significant increase when comparing homozygotes versus individuals carrying other genotypes: HEPC -582GG (EDSS, 4.24±2.87 vs 2.78±2.1; P=0.003; MSSS, 5.6±3.06 vs 3.79±2.6; P=0.001); FPN1-8GG (PI, 1.11±2.01 vs 0.6±1.31; P=0.01; MSSS, 5.08±2.98 vs 3.85±2.8; P=0.01); HFE 63DD (PI, 1.63±2.6 vs 0.6±0.86; P=0.009). Finally, HEPC -582G-carriers had a significantly higher chance to switch into the progressive form (HR=3.55; 1.83-6.84; log-rank P=0.00006). Polymorphisms in the genes coding for iron binding and transporting proteins, in the presence of local iron overload, might be responsible for suboptimal iron handling. This might account for the significant variability peculiar to MS phenotypes, particularly affecting MS risk and progression paving the way for personalized pharmacogenetic applications in the clinical practice.


  • Open Access

    Genetic Association and Altered Gene Expression of Mir-155 in Multiple Sclerosis Patients

    by Elvezia Maria Paraboschi, Giulia Soldà, Donato Gemmati, Elisa Orioli, Giulia Zeri, Maria Donata Benedetti, Alessandro Salviati, Nadia Barizzone, Maurizio Leone, Stefano Duga, et al.

    Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system characterized by chronic inflammation, demyelination, and axonal damage. As microRNA (miRNA)-dependent alterations in gene expression in hematopoietic cells are critical for mounting an appropriate immune response, miRNA deregulation may result in defects in immune tolerance. In this frame, we sought to explore the possible involvement of miRNAs in MS pathogenesis by monitoring the differential expression of 22 immunity-related miRNAs in peripheral blood mononuclear cells of MS patients and healthy controls, by using a microbead-based technology. Three miRNAs resulted >2 folds up-regulated in MS vs controls, whereas none resulted down-regulated. Interestingly, the most up-regulated miRNA (mir-155; fold change = 3.30; P = 0.013) was previously reported to be up-regulated also in MS brain lesions. Mir-155 up-regulation was confirmed by qPCR experiments. The role of mir-155 in MS susceptibility was also investigated by genotyping four single nucleotide polymorphisms (SNPs) mapping in the mir-155 genomic region. A haplotype of three SNPs, corresponding to a 12-kb region encompassing the last exon of BIC (the B-cell Integration Cluster non-coding RNA, from which mir-155 is processed), resulted associated with the disease status (P = 0.035; OR = 1.36, 95% CI = 1.05–1.77), suggesting that this locus strongly deserves further investigations.


  • Nanoengineering Approaches to Design Advanced Dental Materials for Clinical Applications

    by Ajay V. Singh, Snigdha Maheshwari, Dario Giovanni, Venkatesh G. Naikmasur, Arpita Rai, A. S. Aditi, W. N. Gade, Varun Vyas, Donato Gemmati, Giulia Zeri, et al.

    The development of dental materials for clinical applications is largely based on complex physicochemical approaches involving traditional energy intensive and chemical routes. However, there is growing attention towards designing new recipes which can shift dental material design from bioinert to bioactive in order to regulate the biological response of biomineralized tissue. This article reviews current nano-engineering approaches and applications to design nanomaterials for advance clinical pplications in dentistry, considering physical properties, aesthetics, surface texture and hierarchical assembly of tooth anatomy. In addition, this article gives an overview about the benefit of micro-nanoscale material design over conventional dental material arising due to advance nanoscale material properties. Biomimetic nano-engineering route via top-down and bottom-up approaches and subsequent opportunities/challenges aiming to future applications are discussed


  • Open Access

    DHFR 19‐bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: Is the risk reduction due to intracellular folate unbalancing?

    by Donato Gemmati, Monica De Mattei, Linda Catozzi, Matteo Della Porta, Maria L. Serino, Cristina Ambrosio, Antonio Cuneo, Simonetta Friso, Mauro Krampera, Elisa Orioli, et al.